BRUKER CORP Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Market Pressures: Life Science research instruments markets faced pressure from U.S. academic funding headwinds, China stimulus delays, global tariffs, pharma pricing, and economic uncertainty, leading to lower second quarter bookings and revenues.
• Innovation: Recent innovations at ASMS, including new instruments enhancing competitive position in proteomics and metabolomics.
• Cost Savings: Announced an expanded cost savings initiative to reduce annual costs by $100 million to $120 million by fiscal year 2026, affecting all business parts.
• Funding and Tariffs: Anticipate visibility on U.S. NIH and NSF funding, settlements between universities and the federal government to resume grants. Tariffs on Swiss imports expected to settle below 39%, with leverage on other factories if needed.

Segment Performance

• BioSpin Group: In the first half of 2025, revenue was $403 million, roughly flat year-over-year. Contributions came from NMR, preclinical imaging, and lab automation, but scientific software was soft.
• CALID Group: First half 2025 revenue was $566 million, increasing in the low teens percentage. Growth was driven by microbiology and infection diagnostics (MALDI Biotyper and Bruker ELITech Molecular Diagnostics), with Applied Mass Spectrometry robust but Life Science Mass Spectrometry soft.
• Bruker Nano: First half 2025 revenue was $509 million, growing in the low single-digit percentage. Spatial Biology contributed, but Advanced X-Ray revenues declined year-over-year; strength in biopharma offset by industrial market weakness.
• BEST Segment: First half 2025 revenues declined in the low teens percentage, net of intercompany eliminations, due to softness in the clinical MRI market and strong prior year comparison for research instruments.

Guidance

• Fiscal Year 2025: Revenues expected in $3.43 billion to $3.50 billion range, organic revenue decline 2%-4%, contribution from acquisitions ~3.5%, foreign currency tailwind 2.5%. Non-GAAP EPS $1.95-$2.05, down 15%-19% from 2024.
• Third Quarter 2025: Expected relatively weak organic revenue performance, mid- to high-single-digits percent decline year-over-year.
• Fiscal Year 2026: Expect significant margin expansion and EPS growth based on cost-cutting initiatives, with potential partial recovery in research instruments markets.

Risks

• Geopolitical/Tariffs: Uncertainties in tariffs, geopolitical risks, foreign currency, and market demand/supply chains impacting CapEx and revenue.
• Market Demand: Delayed biopharma and industrial research instrumentation investments due to economic uncertainty and tariffs.

Question and Answer

• Q: Parsing backlog and recovery expectations A: Backlog has come down slightly, expecting Q4 to be manageable, but Q3 still weak; visibility on 2026 growth not yet available.
• Q: UHF magnets and acquisition impact A: Ultra-high field revenue recognition expected in Q4; impact of BD microbiology acquisition on MALDI sales speculative.
• Q: Cost-out timing and commitment A: Initial cost savings plan started, expanded to $100M-$120M, committed regardless of market conditions.
• Q: China stimulus and U.S. academic funding A: China stimulus not released yet for high-end research instrumentation; U.S. academic funding expected down, but some signs of improvement.
• Q: Second half cadence and visibility A: Fourth quarter typically sees significant ramp, confident in 2025 fourth quarter performance due to cost savings and historical patterns.
• Q: Tariff assumptions A: Modeling tariffs at lower rates than 39%, with flexibility to shift supply chain if needed.